



Standardising the biochemical confirmation of adult male hypogonadism; a joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine*

Channa N Jayasena¹ , Nipun Lakshitha de Silva¹, Michael W O'Reilly²,
Finlay MacKenzie³, Rachel Marrington⁴ , Hugh Jones⁵, Mark Livingston^{6,7},
Paul Downie⁸, Geoff Hackett⁹, Sud Ramachandran¹⁰, Jeremy Tomlinson¹¹,
Janine David¹², Christopher Boot¹³ , Mayur Patel¹⁴, Julie Tarling¹⁵, Fredrick Wu¹⁶ and
Richard Quinton¹⁷ 

Abstract

Background: Inter-assay variation between different immunoassays and different mass spectrometry methods hampers the biochemical confirmation of male hypogonadism. Furthermore, some laboratories utilise assay manufacturer reference ranges that do not necessarily mirror assay performance characteristics, with the lower limit of normality ranging from 4.9 nmol/L to 11 nmol/L. The quality of the normative data underlying commercial immunoassay reference ranges is uncertain.

¹Department of Metabolism, Digestion and Reproduction, Imperial College, London, UK

²Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Dublin, Ireland

³University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

⁴Birmingham Quality (UK NEQAS), University Hospitals NHS Foundation Trust, Birmingham, UK

⁵Department of Biochemistry, Royal Hallamshire Hospital, University of Sheffield Medical School, Sheffield, UK

⁶Department of Clinical Biochemistry, Black Country Pathology Services, Walsall Manor Hospital, Walsall, UK

⁷School of Medicine and Clinical Practice, Faculty of Science & Engineering, The University of Wolverhampton, Wolverhampton, UK

⁸Department of Clinical Biochemistry, Bristol Royal Infirmary, Bristol, UK

⁹Department of Urology, Spire Hospital Little Aston, Birmingham, UK

¹⁰Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, West Midlands, UK

¹¹Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, UK

¹²Porthcawl Medical Centre & Department of Urology, Princess of Wales Hospital, Bridgend, UK

¹³Department of Blood Sciences, Royal Victoria Infirmary, Newcastle upon Tyne, UK

¹⁴Great Western Hospital NHS Foundation Trust, Swindon, UK

¹⁵Bedfordshire Hospitals NHS Foundation Trust, Luton, UK

¹⁶Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

¹⁷Department of Endocrinology, Diabetes & Metabolism, Newcastle-upon-Tyne Hospitals NHS Foundation Trust & Translational & Clinical Research Institute, University of Newcastle-upon-Tyne, Newcastle Upon Tyne, UK

*This article has been published simultaneously in *Clinical Endocrinology and Annals of Clinical Biochemistry: International Journal of Laboratory Medicine*.

Corresponding author:

Channa N Jayasena, Imperial College Faculty of Medicine, Hammersmith Hospital, 6th Floor Commonwealth building, Du Cane Road, London W12 0NN, UK.

Email: c.jayasena@imperial.ac.uk

Design: A working group reviewed published evidence and agreed upon standardised reporting guidance to augment total testosterone reports.

Results: Evidence-based guidance on appropriate blood sampling, clinical action limits, and other major factors likely to affect the interpretation of results are provided.

Conclusions: This article aims to improve the quality of the interpretation of testosterone results by non-specialist clinicians. It also discusses approaches for assay harmonisation which have been successful in some but not all healthcare systems.

Keywords

Male hypogonadism, testosterone, assay

Accepted: 12th May 2023

Problem statement

Male Hypogonadism comprises clinical features and laboratory evidence of impaired testosterone secretion and reduced fertility.¹ The diagnosis poses challenges to the clinician due to its non-specific symptomatology in some and, more importantly in relation to the UK healthcare environment, due to surprising uncertainties in relation to the biochemical diagnosis. Total testosterone, the most frequently used biochemical marker to diagnose male hypogonadism, like many hormones, is influenced by several biological factors including diurnal variation, circannual rhythms, food intake, acute illness and medications. Moreover, total testosterone measurement has limitations in male with sex hormone-binding globulin (SHBG) levels outside the reference range.

Total testosterone measurement is performed using immunoassays or mass spectrometry (MS) in most UK healthcare facilities. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is considered the method of choice with potentially higher sensitivity and specificity;² however, some MS assays are outperformed by the best immunoassays (Unpublished data from the United Kingdom National External Quality Assessment Service-UKNEQAS). A significant inter-assay variation has been observed between different immunoassays and different MS units in the UK,³ with intra-assay variability being another technical limitation. Superimposed on this is a wide variability in the reference ranges provided by laboratories that do not necessarily mirror assay performance characteristics, with the lower limit of normality ranging from 4.9 nmol/L to 11 nmol/L.³ The quality of the normative data underlying commercial immunoassay reference ranges is uncertain in respect of the population sampled and pre-analytical factors affecting testosterone levels outlined above. Therefore, commercially produced reference ranges have no discernible clinical value for the management of male hypogonadism.

These biological and analytical variables have led to a substantial variation in the practice pertaining to the diagnosis of male hypogonadism. Having noticed these

variations, the Society for Endocrinology and Association for Clinical Biochemistry and Laboratory Medicine commissioned this joint position statement. This aims to provide evidence-based recommendations as a guide to clinicians assessing men with possible hypogonadism. Clinicians have a responsibility for ensuring the correct classification of the type of hypogonadism, identifying the aetiology, appropriate prescription and monitoring of testosterone for men with hypogonadism in line with current guidelines; these aspects are beyond the purview of the current position statement.

Recommendations

Total testosterone levels should be tested in men with symptoms of adult male hypogonadism, using morning, fasting blood samples when the patient is not acutely ill. Testosterone levels vary during the day with a pattern showing higher levels in the morning and lower levels in the afternoon.^{4,5} However, this pattern does not occur in nightshift workers because the diurnal rhythm is primarily driven by sleeping patterns, and not endogenously by circadian factors.⁶ Since testosterone levels decrease after meals and with restricted sleep,⁷ clinicians and laboratory staff should generally advise patients to obtain morning-fasting samples after a good night's rest.^{8,9} Laboratory confirmation of hypogonadism in male shift workers is complicated and warrants specialist referral. Testosterone levels drop during acute illness; therefore, it is not recommended to test during acute illness.^{10,11} When testosterone levels were followed up longitudinally in the same person, a marked day-to-day variation also had been observed;⁴ therefore, a low total testosterone value generally requires confirmation with a repeat measurement.

As of now, a single reference range or cut-off value is not appropriate in the UK due to the variability of the immunoassays used and their associated reference ranges. However, the following threshold values will function as action cut-off values for

clinical practice rather than reference ranges. Patients with suggestive clinical features and two consecutive morning fasting levels <8 nmol/L are likely to have hypogonadism. Though there are no studies directly comparing different testosterone cut-off levels for intervention, total testosterone <8 nmol/L correlates well with sexual symptoms of male hypogonadism and there is strong evidence in this group for a high prevalence of complications of hypogonadism and symptomatic improvement with treatment.^{12–17} Most of the current guidelines also agree with this action limit.^{1,18} Further assessment for the aetiology of hypogonadism is required in these men.

Morning, fasted levels of 8–12 nmol/L may be seen in eugonadal or hypogonadal men, and so require careful clinical correlation.¹⁵ Additionally, discussing with the local biochemistry provider would be helpful in borderline cases to understand whether the assay used is a more positively or negatively biased one. Guidelines agree that total testosterone >12 nmol/L is unlikely to represent hypogonadism.^{1,19} One exception would be when the luteinising hormone (LH) level is raised and there is a concern about subclinical/compensated primary hypogonadism, or androgen receptor cytosine-adenine-guanine (CAG) repeat polymorphism.^{20–22} Even then, there is little evidence for benefit of testosterone replacement therapy in men with serum testosterone >12 nmol/L.

When SHBG is in the reference range, calculated free testosterone has no diagnostic value beyond total testosterone. When SHBG is above the reference range, calculated free testosterone may help diagnose hypogonadism despite normal total testosterone levels.²³ When SHBG is below the reference range, calculated free testosterone may help exclude hypogonadism despite low total testosterone levels. Therefore, it is recommended to check SHBG in men with conditions likely to cause abnormal SHBG and men with borderline total testosterone.²⁴

Direct measurement of free testosterone using equilibrium dialysis followed by MS is considered the reference method for estimating free testosterone.² This method is not available in the UK for routine clinical practice and other direct measurement methods tend to be inaccurate and are not recommended.

The above recommendations are summarised in panel 1.

Panel 1: Standard comments for aiding interpretation of serum testosterone reports

Patients with suggestive clinical features and two consecutive morning, fasted levels <8 nmol/L are likely to have hypogonadism. Morning, fasted levels of 8–12 nmol/L may be seen in eugonadal or hypogonadal men, and so require careful clinical correlation. Levels >12 nmol/L are not usually consistent

with hypogonadism. One reading >12 nmol/L usually excludes hypogonadism, even if other readings are lower.

Measurements in a non-fasted state, during acute illness, or later than 11 a.m. cannot be used to diagnose male hypogonadism. Laboratory bias or nightshift working may affect the results.

When SHBG is within the reference range, calculated free testosterone has no diagnostic value beyond total testosterone. When SHBG is above the reference range, calculated free testosterone may help diagnose hypogonadism despite normal testosterone levels. When SHBG is below the reference range, calculated free testosterone may help exclude hypogonadism despite low testosterone levels.

Clinicians take responsibility for ensuring the appropriate prescription and monitoring of testosterone for men with hypogonadism in line with current guidelines.

Future directions

Developing harmonised reference ranges for testosterone in all the laboratories in the UK would minimise variation among clinicians and centres in the diagnostic approach and make treatment thresholds more robust. Generating harmonised reference ranges using a reference LC-MS/MS method has shown that most of the inter-cohort variation in reference ranges in large population studies was related to assay variation.²⁵

Another option is developing method-specific reference ranges for total testosterone using a reference method such as LC-MS/MS similar to cortisol cut-off values in the cosyntropin stimulation test.²⁶ However, these solutions need intensive technical and human resources, limiting their implementation in near future.

The place of age-specific reference ranges and the need for cut-off values for men with and without obesity still remain unanswered.²⁵ We recommend following the above guidance until more data appears in this field.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CJ received investigator-led grants from Logixx Pharma Ltd and Medac pharma Ltd. HJ attended an advisory board of Medac Pharma Ltd. PD received honoraria from Besins Healthcare. GH received grants from Besins Healthcare, Bayer and Teds Health. SR received travel grants and speakers' honoraria from Besins Healthcare. JD received

honoraria from Besins Healthcare, Bayer and Sanofi. RQ received honoraria from Bayer Ltd, Besins Healthcare, Sandoz and Thornton & Ross. Other authors have no conflicts of interest to declare.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the Society for Endocrinology. The Section of Endocrinology and Investigative Medicine is funded by grants from the MRC, NIHR and is supported by the NIHR Biomedical Research Centre Funding Scheme and the NIHR/Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The following author is also funded by; CNJ: NIHR post-doctoral fellowship.

Ethical approval

Not applicable.

Guarantor

CJ.

Contributorship

CJ and RQ chaired the “Thresholds and Reporting of Testosterone of Male Hypogonadism group” appointed by the Society for Endocrinology. MR, FM, RM, HJ, ML, PD, GH, SR, JT, JD, CB, MP, JT, and FW were members of the group. NS wrote the initial draft and all the authors revised the article. All authors agreed on the final article.

ORCID iDs

Channa N Jayasena  <https://orcid.org/0000-0002-2578-8223>
 Rachel Marrington  <https://orcid.org/0000-0003-1045-8456>
 Christopher Boot  <https://orcid.org/0000-0002-4234-8545>
 Richard Quinton  <https://orcid.org/0000-0002-4842-8095>

References

- Jayasena CN, Anderson RA, Llahana S, et al. Society for endocrinology guidelines for testosterone replacement therapy in male hypogonadism. *Clin Endocrinol* 2022; 96: 200–219.
- Jasuja R, Pencina KM, Peng L, et al. Accurate measurement and harmonized reference ranges for total and free testosterone levels. *Endocrinol Metab Clin North Am* 2022; 51: 63–75.
- Livingston M, Downie P, Hackett G, et al. An audit of the measurement and reporting of male testosterone levels in UK clinical biochemistry laboratories. *Int J Clin Pract* 2020; 74: e13607.
- Brambilla DJ, O'Donnell AB, Matsumoto AM, et al. Intra-individual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. *Clin Endocrinol (Oxf)* 2007; 67: 853–862.
- Bremner WJ, Vitiello Mv and Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. *J Clin Endocrinol Metab* 1983; 56: 1278–1281.
- Kelly MR, Yuen F, Satterfield BC, et al. Endogenous diurnal patterns of adrenal and gonadal hormones during a 24-hour constant routine after simulated shift work. *J Endocr Soc* 2022; 6: bvac153. doi:10.1210/jendso/bvac153.
- Liu PY and Reddy RT. Sleep, testosterone and cortisol balance, and ageing men. *Rev Endocr Metab Disord* 2022; 23: 1323–1339.
- Lehtihet M, Arver S, Bartuseviciene I, et al. S-testosterone decrease after a mixed meal in healthy men independent of SHBG and gonadotrophin levels. *Andrologia* 2012; 44: 405–410.
- Caronia LM, Dwyer AA, Hayden D, et al. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. *Clin Endocrinol (Oxf)* 2013; 78: 291–296.
- Spratt DI, Cox P, Orav J, et al. Reproductive axis suppression in acute illness is related to disease severity. *J Clin Endocrinol Metab* 1993; 76: 1548–1554.
- Woolf PD, Hamill RW, McDonald Jv, et al. Transient hypogonadotropic hypogonadism caused by critical illness. *J Clin Endocrinol Metab* 1985; 60: 444–450.
- Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med* 2010; 363: 123–135.
- Zitzmann M, Faber S and Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. *J Clin Endocrinol Metab* 2006; 91: 4335–4343.
- Hudson J, Cruickshank M, Quinton R, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. *Lancet Healthy Longev* 2022; 3: e381–e393.
- Arver S and Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. *Front Horm Res* 2009; 37: 5–20.
- Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. *Eur Urol* 2017; 72: 1000–1011.
- Buvat J, Maggi M, Guay A, et al. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. *J Sex Med* 2013; 10: 245–284.
- Dean JD, McMahon CG, Guay AT, et al. The international society for sexual medicine's process of care for the assessment and management of testosterone deficiency in adult men. *J Sex Med* 2015; 12: 1660–1686.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2018; 103: 1715–1744.
- Ventimiglia E, Ippolito S, Capogrosso P, et al. Primary, secondary and compensated hypogonadism: a novel risk stratification for infertile men. *Andrology* 2017; 5: 505–510.

21. Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. *J Clin Endocrinol Metab* 2010; 95: 1810–1818.
22. Tirabassi G, Cignarelli A, Perrini S, et al. Influence of CAG repeat polymorphism on the targets of testosterone action. *Int J Endocrinol* 2015; 2015: 298107.
23. Bhasin S and Ozimek N. Optimizing diagnostic accuracy and treatment decisions in men with testosterone deficiency. *Endocr Pract* 2021; 27: 1252–1259.
24. Guzelce EC, Galbiati F, Goldman AL, et al. Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders. *Best Pract Res Clin Endocrinol Metab* 2022; 36: 101683.
25. Travison TG, Vesper HW, Orwoll E, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. *J Clin Endocrinol Metab* 2017; 102: 1161–1173.
26. El-Farhan N, Pickett A, Ducroq D, et al. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. *Clin Endocrinol (Oxf)* 2013; 78: 673–680.